Filing Flows › Fulgent Genetics (FLGT) › Q2 2026 › vs Q2 2025
Fulgent Genetics (FLGT) Q2 2026 vs Q2 2025 (year over year)
Fulgent Genetics's revenue rose $3.6M (+4%) from $81.8M in Q2 2025 to $85.4M in Q2 2026. The biggest changes: Laboratory Services +$3.6M (+4%); Therapeutic Development +$30K (—).
Fulgent Genetics, Q2 2026: revenue $85.4M (+4% year over year), operating margin -42.2%, net loss $29.7M, operating cash flow −$23.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Laboratory Services | $85.4M | $81.8M | $3.6M | +4% |
| Therapeutic Development | $30K | $0 | $30K | — |
| Revenue | $85.4M | $81.8M | $3.6M | +4% |
| Other income, net | $6.4M | −$1.8M | $8.2M | — |
| Net loss | $29.7M | $19.3M | $10.5M | +54% |
| Costs & expenses | $121M | $103M | $18.2M | +18% |
| Operating costs | $121M | $102M | $19.9M | +20% |
| Income tax | $29K | −$2.3M | $2.3M | — |
| Cost of revenue | $59.7M | $47.4M | $12.3M | +26% |
| Research & development | $14.6M | $13.5M | $1.1M | +8% |
| Sales & marketing | $15.2M | $12.3M | $2.9M | +24% |
| General & admin | $27.2M | $26.4M | $803K | +3% |
| Other operating costs | $4.8M | $2.0M | $2.8M | +140% |
| Operating cash sources | $40.1M | $46.3M | −$6.2M | -13% |
| Depreciation & amortization | $7.7M | $6.1M | $1.6M | +27% |
| Share-based compensation | $8.6M | $10.0M | −$1.4M | -14% |
| Cash used in operations | $23.8M | $30.2M | −$6.4M | -21% |
| Net loss absorbed | $29.7M | $19.3M | $10.5M | +54% |
| Working capital & other | $10.3M | $27.0M | −$16.7M | -62% |
Questions
How much did Fulgent Genetics's revenue grow year over year in Q2 2026?
Fulgent Genetics's revenue rose $3.6M (+4%) from $81.8M in Q2 2025 to $85.4M in Q2 2026.
What drove Fulgent Genetics's revenue change in Q2 2026?
Laboratory Services +$3.6M (+4%); Therapeutic Development +$30K (—).